tbuckley/cabot-search huggingface dataset:
Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level
Authors: Stephen C. Lazarus, Jerry A. Krishnan, Tonya S. King, Jason E. Lang, Kathryn V. Blake, Ronina Covar, Njira Lugogo, Sally Wenzel, Vernon M. Chinchilli, David T. Mauger, Anne-Marie Dyer, Homer A. Boushey, John V. Fahy, Prescott G. Woodruff, Leonard B. Bacharier, Michael D. Cabana, Juan C. Cardet, Mario Castro, James Chmiel, Loren Denlinger, Emily DiMango, Anne M. Fitzpatrick, Deborah Gentile, Annette Hastie, Fernando Holguin, Elliot Israel, Daniel Jackson, Monica Kraft, Craig LaForce, Robert F. Lemanske, Fernando D. Martinez, Wendy Moore, Wayne J. Morgan, James N. Moy, Ross Myers, Stephen P. Peters, Wanda Phipatanakul, Jacqueline A. Pongracic, Loretta Que, Kristie Ross, Lewis Smith, Stanley J. Szefler, Michael E. Wechsler, Christine A. Sorkness
Journal: New England Journal of Medicine (2019)

In many patients with mild, persistent asthma, the percentage of eosinophils in sputum is less than 2% (low eosinophil level). The appropriate treatment for these patients is unknown.
SAFETY AND EFFICACY OF THE THULIUM AND ERBIUM LASER SYSTEM ON BLEEDING VASCULAR LESIONS OF THE GI TRACT: A REAL-LIFE MULTI-CENTRE STUDY
Authors: GE Tontini, L Dioscoridi, A Rimondi, P Cantù, F Cavallaro, L Elli, L Pastorelli, F Pugliese, M Mutignani, M Vecchi
Journal: Endoscopy (2019)

Recent pilot studies assessed the feasibility of the Thulium and Erbium laser system (TELS) for endoscopic haemostasis, ablation and resection. Herein, we investigated for the first time ever, the safety and efficacy of endoscopic treatment with TELS in patients with gastrointestinal bleeding due to vascular lesions.
Protroca: A non-interventional study on prophylaxis of chemotherapy induced neutropenia using lipegfilgrastim in non-selected breast cancer patients
Authors: R. Wuerstlein, N. Harbeck, E.-M. Grischke, D. Forstmeyer, R. von Schumann, P. Krabisch, U. Nitz, O. Gluz, R.E. Kates, M. Graeser
Journal: Annals of Oncology (2019)

Background: WSG (West German Study Group)-Protroca evaluated the efficacy and safety of primary and secondary prophylaxis (ppx) of neutropenia with lipegfilgrastim (Lonquex®) in breast cancer (BC) patients (pts) receiving neo-adjuvant or adjuvant treatment in routine praxis. Methods: Eligibility: histologically confirmed BC pts, age ≥18 years, prior or concurrent neo-adjuvant or adjuvant treatment with dose-dense chemotherapy (CT), or with moderate risk CT with risk factors (age >65 years, severe co-morbidities). Primary endpoint: occurrence rate of febrile neutropenia (FN) and/or severe infection (SI) (grade 3–4). Secondary endpoints: dose reductions of further CT or cycle postponement of CT after start of Lonquex® treatment, adverse events (AEs) and serious adverse events (SAEs) related to Lonquex® according to NCI-CTCAE Version 4.0. 47.3% (15.4%) and 38.7% (69.2%) of pts with primary (secondary) ppx received anthracycline (A)-containing dose-dense and A-containing conventionally dense regimen, respectively. Results: Of the 255 enrolled pts (2015–2017), 248 pts were evaluable for the intent to treat (ITT) set (222 and 26 pts with primary and secondary ppx, respectively). 5 pts of the ITT set receiving Lonquex® as primary ppx had FN grade 3–4 (2.3%). Regarding SI, 5 pts of the ITT population (2.0%) had an infection of grade 3–4; 4 pts got primary ppx (1.8%) and one received secondary ppx (3.9%). Dose reductions were only performed in 9.5% of pts (all of them receiving primary ppx). Postponement of CT cycles for >3 days was observed in 14.4% and 11.5% of pts with Lonquex® as primary and secondary ppx, respectively. 67.6% (84.6%) and 6.3% (11.5%) of ITT pts with primary (secondary) ppx exhibited AEs and SAEs, respectively. 10.8% (92/851 AEs) and 8% (2/25 SAEs of 851 AEs) of documented AEs and SAEs, respectively, were related to Lonquex®. Conclusions: In WSG-Protroca, the application of Lonquex® was effective as primary and secondary ppx in the prevention of CT-induced neutropenia. Observed adverse drug reactions and AEs were in line with the Lonquex® summary of product characteristics and CT, respectively; no new toxicities were identified. Legal entity responsible for the study: West German Study Group (WSG). Funding: Teva Biotech GmbH. Disclosure: R. Wuerstlein: Agendia, Amgen, AZ, BI, Carl Zeiss, Celgene, Daiichi-Sankyo, Esai, GE, GSK, Hexal, Lilly, MSD, Mundipharma, NanoString, Novartis, Odonate, Paxman, Palleos, Pfizer, Pierre Fabre, Puma Biotechnology, Riemser, Roche, Sandoz, Seattle Genetics, Tesaro Bio, Teva. N. Harbeck: Honoraria for consulting: Amgen, Hexal. U. Nitz: Honoraria: Genomic Health, Roche. O. Gluz: Honoraria: Genomic Health, NanoString Technologies, Roche; Travel, accommodations, expenses: Celgene; Teva. All other authors have declared no conflicts of interest.
Annals Consult Guys - Cardiovascular Risk, Blood Pressure, and Cognition in a Patient With Diabetes
Authors: Geno J. Merli, Howard H. Weitz
Journal: Annals of Internal Medicine (2019)

Web Exclusives21 May 2019Annals Consult Guys - Cardiovascular Risk, Blood Pressure, and Cognition in a Patient With DiabetesFREEGeno J. Merli, MD and Howard H. Weitz, MDGeno J. Merli, MDThomas Jefferson University, Philadelphia, Pennsylvania (G.J.M., H.H.W.)Search for more papers by this author and Howard H. Weitz, MDThomas Jefferson University, Philadelphia, Pennsylvania (G.J.M., H.H.W.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W18-0044 SectionsSupplemental MaterialAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Annals Consult Guys brings a new perspective to the art and science of medicine with lively discussion and analysis of real-world cases and situations. They address medically relevant topics—whether they be poignant, thought-provoking, or just plain entertaining.For more videos from and information on Annals Consult Guys, visit go.annals.org/ConsultGuys. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Thomas Jefferson University, Philadelphia, Pennsylvania (G.J.M., H.H.W.)Disclosures: Geno J. Merli, MD, reports the following: Research grants/contracts: Bristol-Myers Squibb. Howard H. Weitz, MD, reports that he has no financial relationships or interests to disclose.Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that her spouse has stock options/holdings with Targeted Diagnostics and Therapeutics. Darren B. Taichman, MD, PhD, Executive Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Catharine B. Stack, PhD, MS, Deputy Editor, Statistics, reports that she has stock holdings in Pfizer, Johnson & Johnson, and Colgate-Palmolive. Christina C. Wee, MD, MPH, Deputy Editor, reports employment with Beth Israel Deaconess Medical Center. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Yu-Xiao Yang, MD, MSCE, Deputy Editor, reports that he has no financial relationships or interest to disclose. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 21 May 2019Volume 170, Issue 10Page: CG1KeywordsBlood pressureCognitionDiagnostic techniquesDisclosureResearch grantsResearch reporting guidelinesRisk management ePublished: 21 May 2019 Issue Published: 21 May 2019 Copyright & PermissionsCopyright © 2019 by American College of Physicians. All Rights Reserved.Loading ...
FEASIBILITY AND EFFICACY OF A NOVEL NEEDLE IN ENDOSCOPIC ULTRASOUND-GUIDED TISSUE SAMPLING FOR PANCREATIC SOLID LESIONS: A PROSPECTIVE RANDOMIZED COMPARATIVE STUDY
Authors: CM Cho, SJ Yeo, AN Seo, HI Bae
Journal: Endoscopy (2019)

Histologic confirmation is crucial in the evaluation of pancreatic solid lesions. Recently, variable needles with different shapes for endoscopic ultrasound-guided tissue sampling (EUS-TS) have been widely used to diagnose pancreatic lesion. However, most needles used currently are made from major companies and expensive. Therefore, it is urgent to develop an inexpensive needle with a novel concept technology. We evaluated the feasibility and efficacy of a newly developed prototype needle in EUS-TS for pancreatic solid lesions comparing the commercially available ones.
Toll-like receptors TLR2 and TLR4 block the replication of pancreatic β cells in diet-induced obesity
Authors: Yewei Ji, Shengyi Sun, Neha Shrestha, Laurel B. Darragh, Jun Shirakawa, Yuan Xing, Yi He, Bethany A. Carboneau, Hana Kim, Duo An, Minglin Ma, Jose Oberholzer, Scott A. Soleimanpour, Maureen Gannon, Chengyang Liu, Ali Naji, Rohit N. Kulkarni, Yong Wang, Sander Kersten, Ling Qi
Journal: Nature Immunology (2019)
PATIENT RADIATION EXPOSURE DURING ENTEROSCOPY-ASSISTED ERCP IN SURGICALLY ALTERED ANATOMY
Authors: T Moreels, O De Ronde, P Deprez, H Piessevaux
Journal: Endoscopy (2019)

To provide data on radiation exposure in patients with surgically altered anatomy undergoing enteroscopy-assisted ERCP (EA-ERCP) during a 3-months registration period in comparison with conventional ERCP (C-ERCP) data.
HIV infection in breast cancer patients from Mozambique: A prospective cohort study
Authors: M.D.R.A. Brandão, A. Guisseve, G. Bata, G. de Morais, M. Alberto, F. Schmitt, C. Lorenzoni, S. Tulsidás, N. Lunet, C. Carrilho
Journal: Annals of Oncology (2019)

Background: Breast cancer (BC) burden is increasing among women living with HIV (HIV+). Yet, data regarding epidemiology, BC presentation, treatment, and prognosis is still scarce, especially among HIV+ BC patients (pts) from developing countries. Methods: This prospective cohort included BC patients diagnosed at the Maputo Central Hospital, Mozambique, from Jan-2015 to Mar-2017. Data on demographics, BC risk factors, co-morbidities, treatment, and survival were prospectively collected. Chi2 and t tests were used to compare categorical and continuous variables, respectively. Time-to-event outcomes were estimated using Kaplan-Meier methods. Survival estimates were compared using log-rank test and Cox proportional hazards models. All tests were two-tailed and results were considered significant if p-value was <.05. Results: Among 205 pts included, 98% were black and 52 (25%) were HIV+. HIV+ pts were younger than HIV- pts (median age: 44.5 vs 51.0 years respectively, p=.002), and most had stage III/IV BC (81% vs 71%, p=.204). Among HIV+ pts, 90% had a CD4+ cells count > 200/μL and 26% were diagnosed at the time of BC. Immunohistochemistry analysis was performed in 152 pts and showed that HIV+ pts had a higher proportion of triple-negative BC (TNBC) compared to HIV- pts (37.5% vs 20.5%, p=.029). Among pts with early BC (EBC), there were no significant differences in local treatments received; yet, HIV+ pts tended to receive a lower chemotherapy (CT) dose-intensity (DI) compared to HIV- pts (DI < 85%: 69.4% vs 50.0%, p=.057). Median overall survival (OS) was 31.0 months (m) in HIV+ pts and 34.0 m in HIV- pts (unadjusted hazard ratio [HR] 1.52, 95% confidence interval [CI] 0.92 – 2.51). In EBC pts, median disease-free survival was 27.0 m in HIV+ pts and 31.0 m in HIV- pts (HR 1.37, 95% CI 0.81-2.31). Conclusions: Our results show that in Southeast Africa the proportion of HIV+ women among BC pts can be very high. These pts were diagnosed at a younger age and had a significantly higher proportion of TNBC compared to HIV- pts. They tended to receive lower CT DI, and their survival was worse as compared to HIV- pts, although not statistically different. This highlights the need for better understanding BC biology in HIV+ pts and to provide effective cancer care to this underserved population. Legal entity responsible for the study: Faculty of Medicine, Eduardo Mondlane University, Mozambique. Funding: NIH AORTIC BIG CAT grant (award number 59-210-6-004). Disclosure: M.D.R.A. Brandão: Research grants to my Institute: Roche, Menarini Silicon Biosystems, Pfizer, Janssen Diagnostics. All other authors have declared no conflicts of interest.
Considerations for Present and Future Research on Former Athlete Health and Well-being
Authors: Zachary Y. Kerr, Avinash Chandran, J. D. DeFreese
Journal: JAMA Network Open (2019)

Vy T. Nguyen, MS; Ross D. Zafonte, DO; Jarvis T. Chen, ScD; Kalé Z. Kponee-Shovein, MPH; Sabrina Paganoni, MD, PhD; Alvaro Pascual-Leone, MD, PhD; Frank E. Speizer, MD; Aaron L. Baggish, MD; Herman A. Taylor Jr, MD; Lee M. Nadler, MD; Theodore K. Courtney, MS; Ann Connor, RN; Marc G. Weisskopf, PhD, ScD
Imaging-proven venous thromboembolism among breast cancer patients in a tertiary hospital in the Philippines from 2010-2015
Authors: A.T.B. Gerona, A.E. Gorospe
Journal: Annals of Oncology (2019)

Background: Venous thromboembolism (VTE) is a common cause of mortality in cancer patients. This paper looks into prevalent characteristic of breast cancer in association with VTE, if any. Methods: Hospital patient database were gathered from 2010-2015 with Venous Dupplex Scan or Computed Tomographic Pulmonary Angiography. Each result were reviewed for final conclusion bearing acute pulmonary embolism or acute thrombosis. Only the first VTE event after the diagnosis of cancer was considered. Results: There were 10,380 CTPA/Venous duplex scan performed for the year 2010-2015, where 916 (8.8%) had positive venous thromboembolism. Of the patients who had positive for venous thromboembolism, 208 (2%) had malignancy. Among all the malignancy-associated venous, majority 17.9% (n = 37) had breast cancer. Mean age for Breast cancer patients who had positive VTE was 60.9(46-84) with majority 64.8% having normal BMI. Most had VTE of lower extremities 75.67%, presented with swelling of extremities 48.6%. Twenty-one patients (57.7%) had VTE within one year of cancer diagnosis, 8(21.6%) had VTE more than two years from cancer diagnosis. Sixteen (43.2%) were alive for more than two years from VTE diagnosis, 14 (37.8%) died within 3 months to one years from VTE diagnosis. During the time of VTE diagnosis, active cancer management were chemotherapy 17 (45.9%), hormonal therapy 12 (32.4%), surgery 4(10.8%), while 4(10.8%) had VTE as the presenting symptom of cancer diagnosis. Among those receiving chemotherapy, 11(64.7%) had VTE during chemotherapy days while 35% had VTE with one month after completion of chemotherapy. Those with hormonal therapy 83.3% had aromatase inhibitor, while only 5.4% received tamoxifen. Conclusions: Breast cancer patients with VTE have normal BMI, presenting as swelling of the lower extremity. VTE presented within one year of cancer diagnosis and were mostly alive for more than two years. Active cancer management during VTE diagnosis was mostly during chemotherapy and hormonal with aromatase inhibitor. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Autism-linked dopamine transporter mutation alters striatal dopamine neurotransmission and dopamine-dependent behaviors
Authors: Gabriella E. DiCarlo, Jenny I. Aguilar, Heinrich J.G. Matthies, Fiona E. Harrison, Kyle E. Bundschuh, Alyssa West, Parastoo Hashemi, Freja Herborg, Mattias Rickhag, Hao Chen, Ulrik Gether, Mark T. Wallace, Aurelio Galli
Journal: Journal of Clinical Investigation (2019)

The precise regulation of synaptic dopamine (DA) content by the DA transporter (DAT) ensures the phasic nature of the DA signal, which underlies the ability of DA to encode reward prediction error, thereby driving motivation, attention, and behavioral learning. Disruptions to the DA system are implicated in a number of neuropsychiatric disorders, including attention deficit hyperactivity disorder (ADHD) and, more recently, autism spectrum disorder (ASD). An ASD-associated de novo mutation in the SLC6A3 gene resulting in a threonine-to-methionine substitution at site 356 (DAT T356M) was recently identified and has been shown to drive persistent reverse transport of DA (i.e., anomalous DA efflux) in transfected cells and to drive hyperlocomotion in Drosophila melanogaster. A corresponding mutation in the leucine transporter, a DAT-homologous transporter, promotes an outward-facing transporter conformation upon substrate binding, a conformation possibly underlying anomalous DA efflux. Here, we investigated in vivo the impact of this ASD-associated mutation on DA signaling and ASD-associated behaviors. We found that mice homozygous for this mutation displayed impaired striatal DA neurotransmission and altered DA-dependent behaviors that correspond with some of the behavioral phenotypes observed in ASD.
YEYUNAL PERFORATION WITH ACHALASIA BALLON IN A PATIENT WITH RING SLIPPAGE AND GASTRIC POUCH OUTLET STENOSIS AFTER BANDED GASTRIC BYPASS
Authors: A Baptista, A Salinas, W García, M Guzman
Journal: Endoscopy (2019)

Banded gastric bypass (BGBP) has resulted in superior long-term weight loss compared with non-banded gastric bypass. Nevertheless occasional silastic ring slippage could result in gastric pouch outlet stenosis (GPOS). Conventional management has been ring removal through abdominal laparoscopic surgery. However, peritoneal adherences could make surgery challenging and increase the risk of complications.
ACUTE CHOLECYSTITIS IN HIGH RISK SURGERY PATIENTS. VALUE OF PERCUTANEOUS CHOLECYSTOSTOMY AND ERCP
Authors: C García-Ramos García, EM Quintanilla Lázaro, I Maestro Prada, P Chaudarcas Castiñeira, M Alvarez Sánchez, JL Castro Urda
Journal: Endoscopy (2019)

Either percutaneous cholecystostomy (PC) and ERCP is recommended in patients with diagnosis of acute calculous cholecystitis (ACC) and high surgical risk. We aimed to compare the outcome of PC and/or ERCP in patient with ACC who are high-risk surgery candidates (HRSC).
Abstract 16210: Protocolized Hemostatic Factor Use in Major Thoracic Aortic Surgery
Authors: Matthew A Wagner, Hanghang Wang, Ehsan Benrashid, Jeffrey E Keenan, Yamini Krishnamurthy, Jerrold H Levy, Ian J Welsby, G. Chad Hughes
Journal: Circulation (2017)

Introduction: The role of purified hemostatic factor concentrates in the management of perioperative bleeding after cardiac surgery remains controversial, mainly due to concerns for thromboembolic ...
TREATMENT OF REFRACTORY POST-SPHINCTEROTOMY AND POST-PAPILLECTOMY BLEEDING BY ENDOSCOPIC FIBRIN GLUE INJECTION. RESULTS OF A LARGE SERIES
Authors: G Valerii, A Tringali, F Borrelli de Andreis, S Greco, V Perri, P Familiari, I Boškoski, G Costamagna
Journal: Endoscopy (2019)

Bleeding is one of the most common complication after endoscopic biliary sphincterotomy (ES) and post-papillectomy. Endoscopic hemostasis can be achieved by epinephrine, hemoclip, thermal coagulation or combining these options. Transarterial embolization (TAE) or even surgery are the last options to control bleeding. Aim of this study is to evaluate the results and the long-term follow-up of treatment of refractory post-sphincterotomy and post-papillectomy bleeding with endoscopic injection of fibrin glue.
PERORAL ENDOSCOPIC MYOTOMY AND SEPTOTOMY (POEM-S) FOR THE TREATMENT OF EPIPHRENIC ESOPHAGEAL DIVERTICULUM. A PILOT STUDY WITH VIDEO
Authors: JM Gonzalez, P Basile, M Barthet
Journal: Endoscopy (2019)

Esophageal diverticula are rare, frequently associated with esophageal dysmotility, and usually managed surgically with high morbidity. We report a series of 6 patients treated by peroral endoscopic submucosal myotomy and septotomy (POEM-S). The objectives were to describe the technique, document its feasibility, safety and clinical efficacy.
Abstract 2921: Critical mediation of E2-induced apoptosis through c-Src in long-term estrogen deprived breast cancer cells
Authors: Ping Fan, Obi L. Griffith, Pavana Anur, Helen R. Kim, Joe W. Gray, V. Craig Jordan
Journal: Cancer Research (2012)

Abstract Our previous publication showed that physiological concentrations of estrogen (E2) could trigger apoptosis of long-term E2 deprived breast cancer cells (MCF-7:5C) (Lewis et al. JNCI 2005; 97:1746-59). This new targeted strategy provides novel therapeutic approaches to endocrine resistant breast cancer. A phase II clinical trial reported that E2 provided a clinical benefit for aromatase inhibitor-resistant advanced breast cancer patients. However, only 30% of patients receive clinical benefit (Ellis MJ et al. JAMA 2009;302:774-80). This prompted us to investigate the mechanisms underlying E2-induced apoptosis to find strategies to increase the therapeutic responsiveness. c-Src is currently of interest, as it is an important adapter protein of ER in breast cancer cells. Here, we found that E2 stimulated c-Src phosphorylation in MCF-7:5C cells and 4-hydroxytamoxifen (4-OHT) could block this stimulation which demonstrated that E2 activated c-Src through ER. The specific inhibitor of c-Src, PP2, could block c-Src activation induced by E2. E2 rapidly activated growth pathways within minutes in MCF-7:5C cells and PP2 could block this non-genomic pathway. E2 was also able to activate Akt/MAPK pathways after 24 hour treatment which could be blocked by inhibition of c-Src. These data showed that c-Src mediated downstream signaling pathways of ER in MCF-7:5C cells. Characteristic E2-induced apoptosis occurred around 72 hour treatment with E2, unexpectedly, inhibition of c-Src could significantly block E2-induced apoptosis which implied that c-Src played a critical role in E2-induced apoptosis. Further examination through transcriptome analysis confirmed that E2 widely induced apoptosis-related pathways. Consistent with the biological experiments, PP2 could completely abolish the apoptosis pathways induced by E2. These data illustrate that c-Src acts as a critical molecule to mediate the downstream signaling of ER (including E2-induced apoptosis) in MCF-7:5C cells. It provides an important rationale for clinical trial with c-Src inhibitors in aromatase inhibitors resistant patients, especially avoiding in combination with physiological levels of E2. Acknowledgements This work (VCJ and JWG) is supported by the SU2C (AACR) Grant (SU2C-AACR-DT0409). Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2921. doi:1538-7445.AM2012-2921